Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAPERS: Conventional vs Total Neoadjuvant Therapy in Older Patients With Rectal Cancer
NCT06052332Recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Feb 2024
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin, fluorouracil and capecitabine in rectal cancer (2 arms), sponsored by Institut Jules Bordet. Primary endpoints: Overall Survival at 3 years, Progression-Free Survival at 3 years and 2 more. Started Feb 2024; status: recruiting.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06052332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052332.